



CE-IVD Xpert® Test Overview

With the GeneXpert® system and the Xpert® test menu, Cepheid delivers actionable results when clinicians need them most.

GeneXpert® System: CE-IVD Test Overview

TEST NAME	INTENDED USE SUMMARY	# TESTS / KIT	TEST RUN TIME (MIN)	TARGETED GENE SEQUENCES	SAMPLE^	SAMPLE STORAGE CONDITION	MINIMUM SOFTWARE VERSION GENEXPERT®	MINIMUM SOFTWARE VERSION INFINITY
Respiratory								
Xpert® Xpress CoV-2/Flu/RSV plus	Detection and differentiation of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV)	10	36*	10	Nasopharyngeal or Anterior nasal swab	15–30 °C for up to 48 hours (VTM, saline/eNAT) 2–8 °C up to seven days (VTM/saline) and up to six days in eNAT	4.7b or higher	6.4b or higher
Xpert Xpress CoV-2 plus	Detection of SARS-CoV-2 in symptomatic and asymptomatic patients	10	30*	3	Nasopharyngeal or Anterior nasal swab†	15–30 °C for up to 48 hours (VTM, Saline/eNAT), (2–8 °C) up to seven days (VTM, Saline/eNAT)	4.7b or higher	6.4b or higher
Xpert Xpress Strep A	Detection of <i>Streptococcus pyogenes</i> from patients with symptoms of pharyngitis	10	24*	1	Throat swab, ESwab™	15–30 °C ≤2 days 2–8 °C ≤6 days	4.7b or higher	6.4b
Xpert Xpress Flu/RSV	Detection and differentiation of Flu A, Flu B, and RSV	10	30*	5	Nasopharyngeal or nasal swabs	Stability in Transport Reagent: 2–30 °C up to 24 hours Stability in Transport Reagent: 2–8 °C for up to 7 days	4.6a or higher	6.4b
Healthcare-Associated Infections & Other Infectious Diseases								
Xpert MRSA NxG	Detection of MRSA directly from nasal swabs in patients at risk for nasal colonization	10 / 120	70*	3	Nasal (Rayon) swab, ESwab™	15–30 °C ≤24 hours 2–8 °C ≤7 days	4.3	6.1
Xpert SA Nasal Complete	Detection of <i>S.aureus</i> and MRSA from nasal swabs in patients at risk for nasal colonization and pre-surgical patients	10 / 120	65	3	Nasal swab	15–30 °C ≤24 hours; 5 days at 2–8 °C	2.1	6.1
Xpert MRSA/SA Blood Culture	Detection of MRSA and <i>S. aureus</i> in positive blood cultures	10	62	3	50 µL positive blood culture bottle	Immediately when culture positive; 2–8 °C, 15–30 °C ≤24 hours, 2–8 °C ≤3 days at 2–8 °C	N/A	5.3
Xpert MRSA/SA SSTI	Detection of MRSA and <i>S. aureus</i> skin and soft tissue infections	10	62	3	Skin/wound swab	15–30 °C ≤24 hours; 5 days at 2–8 °C	1.6	6.1
Xpert Carba-R	Detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48	10 / 120	50	5	Pure colonies, rectal and perirectal swab specimens	Swabs in the transport tube: 15–28 °C <5 days Fresh isolates after an incubation of 18–24 hours at 35 °C	4.3	6.1
Xpert Norovirus	Identification and differentiation of Norovirus GI and GII	10	88*	2	Raw or unpreserved unformed stool specimen	2–8 °C ≤2 days	4.3	6.1
Xpert EV	Detection of enteroviruses in CSF	10	150	1	Cerebrospinal fluid	2–8 °C ≤3 days, -20 °C ≤3 days	1.6	N/A
Xpert C. difficile BT	Detection of <i>Clostridioides difficile</i> and its binary toxin plus the differentiation of the 027 strain	10	43	3	Swab from unformed stool specimens	20–30 °C <24 hours, 2–8 °C <5 days	4.3	6.1
Xpert vanA/vanB	Detection of vancomycin-resistance (<i>vanA-vanB</i>) genes	10	48	2	Rectal or peri-anal swab	2–8 °C <5 days	1.6b	6.1

GeneXpert® System: CE-IVD Test Overview (continued)

TEST NAME	INTENDED USE SUMMARY	# TESTS / KIT	TEST RUN TIME (MIN)	TARGETED GENE SEQUENCES	SAMPLE [^]	SAMPLE STORAGE CONDITION	MINIMUM SOFTWARE VERSION GENEXPERT®	MINIMUM SOFTWARE VERSION INFINITY
TB & Emerging Infectious Diseases								
Xpert MTB/RIF	Detection of <i>Mycobacterium tuberculosis</i> complex and Rifampin-resistance associated mutations	10 / 50	105	5	Sputum sample or concentrated sediment	≤35 °C ≤ 3 days; 2–8 °C for 7 additional days	4.3	6.0
Xpert MTB/RIF Ultra	Detection of <i>Mycobacterium tuberculosis</i> complex and Rifampin-resistance associated mutations	10 / 50	80	6	Sputum sample or concentrated sediment	≤35 °C up to 3 days; 2–8 °C for 4 to 10 days	4.7b or higher	6.4b
Xpert MTB/XDR	Detection of <i>Mycobacterium tuberculosis</i> complex and mutations associated with drug resistance towards Isoniazid, Fluoroquinolones, Second-Line Injectable Drugs and Ethionamide	10	90	8	Sputum sample, concentrated sediment or MGIT culture	Unprocessed Sputum: 2–35 °C up to 7 days Sputum Sediment: 2–8 °C up to 7 days Specimen treated with sample reagent ≤35 °C up to 2.5 hrs, 2–8 °C up to 4 hrs	6.2 or higher	N/A
Xpert Ebola	Detection of Ebola Zaire virus	10 / 50	94	2	Venous whole blood, peripheral blood from fingerstick, buccal swab†	Reagent-treated blood samples: 2–8 °C ≤3 days; ≤28 °C ≤48 hours; ≤35 °C ≤24 hours; Reagent-treated buccal swab samples: 2–8 °C ≤72 hours; ≤28 °C ≤24 hours	4.4a	6.2
Blood Virology, Women's Health, & Sexual Health								
Xpert CT/NG	Detection and differentiation of genomic DNA from <i>Chlamydia trachomatis</i> (CT) and/or <i>Neisseria gonorrhoeae</i> (NG)	10 / 120	88	3	Urine or swab (vaginal/ endocervical swab or pharyngeal or rectal swab)	Urine in validated transport tube — M: 2–30 °C ≤45 days; F: 2–30 °C ≤3 days; 2–15 °C ≤45 days Swab — M/F: 2–30 °C ≤60 days	4.3	6.0
Xpert HPV	Detection of high risk Human Papillomavirus (HPV) — identifies types HPV 16 and HPV 18/45; reports 11 other high risk types in a pooled result	10	56	5	Cervical specimens collected with PreservCyt solution	2–30 °C ≤6 months	4.3	6.1
Xpert GBS	Detection of <i>Group B Streptococcus</i> (GBS)	10	56	1	Both vaginal and rectal swab	Room temperature ≤24 hours; 2–8 °C ≤6 days	N/A	N/A
Xpert Xpress GBS	Detection of <i>Group B Streptococcus</i> (GBS)	10	42*	2	Both vaginal and rectal swab	Room temperature ≤24 hours; 2–8 °C ≤6 days		
Xpert TV	Detection of <i>Trichomonas vaginalis</i> (TV)	10	64*	1	Urine or vaginal/endocervical swab	Urine in validated transport tube: 2–8 °C ≤28 days (F/M); 15–30 °C ≤14 days (F/M) Swabs: 2–30 °C ≤60 days	4.3	N/A

GeneXpert® System: CE-IVD Test Overview (continued)

TEST NAME	INTENDED USE SUMMARY	# TESTS / KIT	TEST RUN TIME (MIN)	TARGETED GENE SEQUENCES	SAMPLE^	SAMPLE STORAGE CONDITION	MINIMUM SOFTWARE VERSION GENEXPERT®	MINIMUM SOFTWARE VERSION INFINITY
Blood Virology, Women's Health, & Sexual Health								
ResistancePlus® MG FleXible#	Detection of <i>M. genitalium</i> and macrolide resistance	10	131	1	Male: urine, urethral and rectal swabs Female: urine, cervical, endocervical, vaginal and high vaginal swabs and rectal swabs	Urine (M/F) in Roche 06466281190: 2–8 °C ≤90 days or 15–30 °C ≤90 days URINE/A Female: 2–15 °C ≤45 days, 2–30 °C ≤3 days URINE/A Male: 2–30 °C ≤45 days Vaginal & cervical swab in SWAB/A: 2–30 °C ≤60 days M/F rectal swab in SWAB/G: 2–30 °C ≤60 days Vaginal, cervical, urethral (M/F) & rectal (M/F) swab in: Copan 306 C: 2–25 °C ≤48 hours or ≤ -70 °C ≥48 hours; Roche 06466281190: 2–8 °C ≤90 days or 15–30 °C ≤90 days	4.7b	6.4b
Xpert HBV Viral Load	Detection and quantitation of Hepatitis B Virus (HBV)	10	57	1	Plasma Serum	EDTA anticoagulated blood can be conserved 24 hours between 15–35 °C or 3 days between 2–8 °C; 2–8 °C, 7 days	4.7b	6.4b
Xpert HCV Viral Load	Detection and quantitation of Hepatitis C Virus (HCV)	10	105	1	Plasma Serum	EDTA anticoagulated blood can be conserved 24 hours between 15–35 °C or 3 days between 2–8 °C; -70 to -18 °C ≤6 weeks	4.7b	6.4b
Xpert HCV VL Fingerstick	Detection and quantitation of Hepatitis C Virus (HCV)	10	57	1	EDTA whole capillary blood — fingerstick EDTA whole venous blood — venipuncture	EDTA capillary blood: 5–35 °C ≤15 minutes; EDTA venous blood: -20 °C ≤6 months; 2–8 °C ≤3 days; ≤35 °C ≤24 hours	4.7b	6.4b
Xpert HIV-1 Qual	Detection of Human Immunodeficiency Virus Type 1 (HIV-1)	10	93	2	EDTA whole blood / Dried blood spot	EDTA whole blood 31–35 °C ≤8 hours; 15–30 °C ≤24 hours, 2–8 °C ≤3 days DBS: 31–35 °C ≤8 weeks; 2–25 °C ≤12 weeks; -15 °C ≤12 weeks	4.7b	6.4b
Xpert HIV-1 Qual XC	Detection of Human Immunodeficiency Virus Type 1 (HIV-1)	10	79 / 91	3	EDTA whole venous blood — venipuncture EDTA whole capillary blood — fingerstick / Heel stick DBS	EDTA venous whole blood 2–8 °C for up to 96 hours or at 2–35 °C for up to 24 hours EDTA capillary whole blood 2–35 °C for up to 60 minutes DBS: 2–25 °C or frozen at -15 °C or colder for up to 16 weeks, or 2–35 °C for up to 8 weeks	4.7b	6.4b
Xpert HIV-1 Viral Load	Detection and quantification of Human Immunodeficiency Virus Type 1 (HIV-1)	10	91	3	Plasma	EDTA anticoagulated blood can be conserved 24 hours between 15–35 °C or 3 days between 2–8 °C; -70 to -18 °C ≤6 weeks	4.7b	6.4b
Xpert HIV-1 Viral Load XC	Detection and quantification of Human Immunodeficiency Virus Type 1 (HIV-1)	10	90	3	Plasma	EDTA whole blood 2–30 °C for up to 24 hours; Plasma 2–35 °C for up to 24 hours, at 2–8 °C for up to 7 days or frozen (≤ -18 °C and ≤ -70 °C) for up to 6 weeks	4.7b	6.4b

GeneXpert® System: CE-IVD Test Overview *(continued)*

TEST NAME	INTENDED USE SUMMARY	# TESTS / KIT	TEST RUN TIME (MIN)	TARGETED GENE SEQUENCES	SAMPLE [^]	SAMPLE STORAGE CONDITION	MINIMUM SOFTWARE VERSION GENEXPERT®	MINIMUM SOFTWARE VERSION INFINITY
Oncology & Genetics								
Xpert Bladder Cancer Detection	Molecular detection of the presence of bladder cancer in patients with hematuria	10	90	5	Voided Urine	Preserved Urine: 2–28 °C ≤7 days	4.7b or higher	6.4b and higher
Xpert Bladder Cancer Monitor	Qualitative monitoring for recurrence in patients previously diagnosed with bladder cancer	10	90	5	Voided Urine	Preserved Urine: 2–28 °C ≤7 days	4.7b or higher	6.4b and higher
Xpert Breast Cancer STRAT4	Semi-quantitative measurement of ESR1, PGR, ERBB2, and MKi67 from FFPE invasive breast cancer tissue	10	70	5	FFPE tissue specimens	FFPE Lysate: -80 °C, long term Scroll, in 1.5 mL tube: 2–8 °C, 14 days Slide Section: 2–8 °C, 28 days Macrodissected section(s), in 1.5 mL tube: 2–8 °C, 14 days	4.7b or higher	6.4b and higher
Xpert BCR-ABL Ultra	Sensitive, standardized and easy to use quantitative monitoring of BCR-ABL mRNA for chronic myeloid leukemia (CML) patients	10	105	2	4 mL whole blood	EDTA: 4 °C, 72 hours	5.1 or higher	6.6 or higher
Xpert BCR-ABL Ultra p190	Quantitation of BCR-ABL1 and ABL1 mRNA transcripts in peripheral blood specimens of diagnosed t(9;22) positive Chronic Myeloid Leukemia (CML) patients expressing BCR-ABL1 fusion transcripts type e13a2 and/or e14a2	10	103	2	4 ml whole blood (EDTA)	EDTA: 2–8 °C for 72 hours	6.2 or higher	N/A
Xpert NPM1 Mutation	Quantification of mutant NPM1 mRNA transcripts (types A, B and D in exon 12) in peripheral blood specimens from patients with acute myeloid leukemia (AML)	10	139	2	4 ml whole blood (EDTA)	EDTA: 2–8 °C for 72 hours	6.2 or higher	N/A
Xpert FII & FV	Diagnostic genotyping test to identify risk factors for thrombosis	10	30	4	50 µL whole blood (EDTA or sodium citrate)	22–28 °C <24 hours; 2–8 °C <15 days; frozen up to 3 months	4.0	6.6

CE-IVD. Medical Devices for *in vitro* Diagnosis. May not be available in all countries. Store all kits at room temperature except Xpert® Norovirus and Xpert® BCR-ABL Ultra (store at 2-8°C).

Xpert® tests are molecular biology tests intended for use by healthcare professionals with the GeneXpert® Systems. Carefully read the instructions in the package insert and in the systems user manual.

* Early Assay Termination (EAT) is available for positive results.

[^] Please refer to the package insert for validated collection tools and/or transport media.

Manufactured by SpeeDx and exclusively distributed by Cepheid

† Follow WHO guidelines for transport of Ebola specimens.

‡ Asymptomatic Screening Available for sample type. Performance of Xpert **Xpress** CoV-2 **plus** for asymptomatic screening population has only been established in anterior nasal swab specimens. Specimen types other than anterior nasal swab have not been assessed and performance characteristics are unknown.

CORPORATE HEADQUARTERS

904 Caribbean Drive
Sunnyvale, CA 94089 USA

TOLL FREE +1.888.336.2743
PHONE +1.408.541.4191
FAX +1.408.541.4192

EUROPEAN HEADQUARTERS

Vira Solelh
81470 Maurens-Scopont France

PHONE +33.563.82.53.00
FAX +33.563.82.53.01
EMAIL cepheid@cepheideurope.fr

www.Cepheidinternational.com

© 2023 Cepheid. 3000-15